x
Norris Cotton Cancer CenterNorris Cotton Cancer Center
In This Section

Lung / Esophageal / Thoracic Cancer Clinical Trials

A clinical trial is one of the final steps in a long and careful cancer research process that is looking for better ways to prevent, diagnose, or treat cancer. Clinical trials test new medical approaches in patients with cancer, and are important to developing new treatments for cancer. Many of the "standard treatments" that patients with cancer receive today were developed based on the results of previous clinical trials.

The following is a list of clinical trials with which this cancer care program is currently involved. Talk to your doctor to find out if a clinical trial is right for you.

Esophagus Clinical Trials
Randomized Phase II Study of Platinum and Etoposide versus Temozolomide and Capecitabine in Patients with Advanced G3 Non-Small Cell Gastroenteropancreatic Neuroendocrine Carcinomas
Esophagus
EA2142
Hourdequin
Lung Clinical Trials
A Feasibility Study of Unsupervised, Pre-operative Exercise Program for Patients Scheduled for Lung Cancer Surgery
Lung
D17044
Lyons
A Phase 1/2, Open-Label, Multicenter Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of Oral Once-Daily Administration of HS-10296 in Patients with Locally Advanced or Metastatic Non-Small-Cell Lung Cancer Who Have Progressed Following Prior Therapy with an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Agent
Lung
F17102
Shirai
A Phase 2 Study of LY2606368 in Patients with Extensive Stage Disease Small Cell Lung Cancer
Lung
F16071
Dragnev
A Phase I Study of IRX4204 in Combination with Erlotinib in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer
Lung
D16047
Dragnev
A Phase II Trial of Trametinib with Docetaxel in Patients with KRAS Mutation Positive Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies
Lung
S1507
Dragnev
A Phase II, Multicenter, Study of Oral cMET Inhibitor INC280 in Adult Patients with EGFR Wild-Type (wt), Advanced Non-Small Cell Lung Cancer (NSCLC)
Lung
F15153
Dragnev
A Phase II, Open-Label, Multicenter, Single-Arm Study to Investigate the Efficacy and Safety of Atezolizumab as Neoadjuvant and Adjuvant Therapy in Patients with Stage IB, II, IIIA, or Selected IIIB Resectable and Untreated Non-Small Cell Lung Cancer
Lung
F17065
Finley
A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Lung
E4512
Dragnev
A Randomized, Phase II/III Trial of Afatinib Plus Cetuximab Versus Afatinib Alone in Treatment-Naive Patients with Advanced, EGFR Mutation Positive Non-Small Cell Lung Cancer (NSCLC)
Lung
S1403
Fuld
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial
Lung
A151216
Dragnev
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)- A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Lung
EA5142
Dragnev
Evaluation of Appeal and Impact of E-Cigarettes Among Chronic Smokers with Smoking-Related Cancers
Lung
D15154
Sargent
Phase 1b/2a Safety and Pharmacokinetic Study of G1T28 in Patients with Previously Treated Extensive-Stage Small Cell Lung Cancer (SCLC) Receiving Topotecan Chemotherapy
Lung
F16186
Dragnev
Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer (Lung-MAP)
Lung
S1400
Dragnev
Phase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited Small Cell Lung Cancer also Receiving Cisplatin or Carboplatin and Etoposide
Lung
C30610
Russo
Phase III Randomized Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin (DOX) versus Cyclophosphamide (CTX), Doxorubicin (DOX) and Vincristine (VCR)(CAV) or Topotecan as Treatment in Patients with Small-Cell Lung Cancer (SCLC) Who Failed One Prior Platinum-Containing Line
Lung
F16146
Dragnev
Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Lung
A081105
Dragnev
Randomized Phase II Trial Evaluating the Optimal Sequencing of PD-1 Inhibition with Pembrolizumab (MK-3475) and Standard Platinum-Based Chemotherapy in Patients with Chemotherapy Naive Stage IV Non-Small Cell Lung Cancer
Lung
H16039
Dragnev
Role of Early F-FDG-PET/CT Scan in Predicting Mediastinal Downstaging with Neoadjuvant Chemotherapy in Resectable Stage III A NSCLC
Lung
EA5123
Dragnev
Other Respiratory and Intrathoracic Organs Clinical Trials
A Randomized Phase III Trial of Endocrine Therapy plus Entinostat/Placebo in Patients with Hormone Receptor-Positive Advanced Breast Cancer
Other Respiratory and Intrathoracic Organs
E2112
Kaufman
Patient and Caregiver Costs Following Hematopoietic Stem Cell Transplantation
Other Respiratory and Intrathoracic Organs
D15165
Meehan

0